HPV Induced Cancers is under clinical development by Theravectys and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HPV Induced Cancers’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HPV Induced Cancers overview
Vaccine candidate is under development for the treatment of HPV-associated cervical, oropharyngeal cancer, anal cancer and throat cancer. It is composed of lentiviral vectors incorporating several tumor-associated antigens that boost the immune response of the body. It is administered through intramuscular route.
Theravectys overview
Theravectys is a biotechnology company that specializes in the development of therapeutic vaccines and immunotherapies. The company’s primary focus is on the creation of lentiviral vectors for the prevention and treatment of cancer and infectious diseases. TheraVecty’s proprietary lentiviral vector immunotherapy is designed to induce high-quality T cell and antibody responses, creating strong and long-term protective or therapeutic immunity. its products for major health issues such as cancer, AIDS, malaria, and tuberculosis. TheraVectys is headquartered in Paris, France.
For a complete picture of HPV Induced Cancers’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
